G1 Therapeutics Past Earnings Performance
Past criteria checks 0/6
G1 Therapeutics's earnings have been declining at an average annual rate of -0.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 48.2% per year.
Key information
-0.7%
Earnings growth rate
4.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 48.2% |
| Return on equity | -135.6% |
| Net Margin | -58.1% |
| Next Earnings Update | 01 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How G1 Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 83 | -48 | 72 | 43 |
| 30 Sep 23 | 78 | -71 | 80 | 52 |
| 30 Jun 23 | 89 | -78 | 88 | 63 |
| 31 Mar 23 | 57 | -126 | 96 | 72 |
| 31 Dec 22 | 51 | -148 | 101 | 83 |
| 30 Sep 22 | 47 | -154 | 101 | 86 |
| 30 Jun 22 | 28 | -171 | 101 | 87 |
| 31 Mar 22 | 24 | -171 | 100 | 85 |
| 31 Dec 21 | 31 | -148 | 96 | 75 |
| 30 Sep 21 | 42 | -134 | 98 | 72 |
| 30 Jun 21 | 64 | -103 | 92 | 69 |
| 31 Mar 21 | 60 | -95 | 81 | 68 |
| 31 Dec 20 | 45 | -99 | 69 | 72 |
| 30 Sep 20 | 29 | -109 | 57 | 81 |
| 30 Jun 20 | 2 | -130 | 50 | 124 |
| 31 Mar 20 | 0 | -130 | 44 | 92 |
| 31 Dec 19 | 0 | -122 | 41 | 88 |
| 30 Sep 19 | 0 | -111 | 35 | 135 |
| 30 Jun 19 | 0 | -99 | 29 | 73 |
| 31 Mar 19 | 0 | -89 | 23 | 70 |
| 31 Dec 18 | 0 | -85 | 19 | 70 |
| 30 Sep 18 | 0 | -78 | 14 | 0 |
| 30 Jun 18 | 0 | -74 | 11 | 0 |
| 31 Mar 18 | 0 | -68 | 9 | 17 |
| 31 Dec 17 | 0 | -65 | 7 | 54 |
| 30 Sep 17 | 0 | -60 | 6 | 0 |
| 30 Jun 17 | 0 | -52 | 5 | 0 |
| 31 Mar 17 | 0 | -45 | 4 | 0 |
| 31 Dec 16 | 0 | -35 | 5 | 0 |
| 31 Dec 15 | 1 | -22 | 3 | 0 |
| 31 Dec 14 | 1 | -7 | 3 | 0 |
Quality Earnings: G1H is currently unprofitable.
Growing Profit Margin: G1H is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: G1H is unprofitable, and losses have increased over the past 5 years at a rate of 0.7% per year.
Accelerating Growth: Unable to compare G1H's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: G1H is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: G1H has a negative Return on Equity (-135.55%), as it is currently unprofitable.